Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have been given a consensus recommendation of “Buy” by ...

Context Therapeutics Inc.’s CNTX share price has surged by 13.22%, which has investors questioning if this is right time to ...

HC Wainwright reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report released ...

CTIM-76 first patient dosed in January 2025Cash and cash equivalents of $94.4 million as of December 31, 2024Company expects its cash and cash ...

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 ...

This Perspective article examines the interplay between antibody diversification mechanisms and highlights the importance of constant regions in influencing the specificity and functionality of ...

HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human ...

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement -- First-in-human study will evaluate the safety, tolerability, ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement -- First-in-human study will evaluate the safety, tolerability ...